@article{thurner:hal-02995983,
TITLE = {Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx},
AUTHOR = {Thurner, L. and Poeschel, V and Haioun, C. and Houot, R. and Gaulard, P. and Molina, T. and Rosenwald, A. and Andre, M. and Hoffmann, J. and Dreyling, M. and Casasnovas, O. and Maisonneuve, H. and Tilly, H. and Illmer, T. and Mayer, S. and Kirchen, H. and La Rosee, P. and Loeffler, M. and Ziepert, M. and Altmann, B and Held, G.},
URL = {https://hal.science/hal-02995983},
JOURNAL = {Oncology Research and Treatment},
VOLUME = {43},
NUMBER = {SUPPL 4},
PAGES = {60-61},
YEAR = {2020},
HAL_ID = {hal-02995983},
HAL_VERSION = {v1},
}